Lytix Biopharma announces positive top-line data from a Phase 1 study with LTX-315
14. desember 2018
Norinnova Invest AS
Forskningsparken
Postboks 6413
9294 Tromsø
Telefon: 90 55 90 01
E-post:karl-johan@norinnovaforvaltning.no
Design: Gnist Design | WordPress